Drug Topics

AUGUST 6, 2024

The COVID-19 pandemic led to increased pharmacist burnout and workforce shortages. The impact is still being felt today.

219

219

STAT

AUGUST 6, 2024

Many chefs describe the television series “The Bear” as an accurate portrayal of the demands of a restaurant kitchen. I believe it can also be seen as a characterization of work in a hospital, in which future physicians are simultaneously gaining remarkable skills and enduring career-altering abuse. For my new book, “Progress Notes,” I spent a couple years observing seven medical students in an experimental curriculum.

Hospitals 143

Hospitals 143

Drug Topics

AUGUST 6, 2024

From expanding vaccination coverage to battling with PBMs, the community pharmacist has the ability to promote change like never before.

Vaccines 205

Vaccines 205

Fierce Healthcare

AUGUST 6, 2024

A federal appeals court has upheld a lower court decision that struck down key parts of legislation aimed at reforming surprise medical billing. | A federal appeals court upheld a lower court decision that struck down key parts of legislation aimed at reforming surprise medical billing.

141

141

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

AUGUST 6, 2024

Researchers tested various text-to-image generation platforms to better understand issues of representation within artificial intelligence.

138

138

STAT

AUGUST 6, 2024

Roche, the Swiss pharmaceutical giant, earlier this year abruptly cancelled an international clinical trial of a drug being studied to treat children with a rare genetic disorder, citing “trade-offs made … to increase the overall portfolio value.” The news stunned parents of children enrolled in the Phase 2 study, as well as the academic researchers running it.

136

136

Fierce Pharma

AUGUST 6, 2024

Warning of a "silent pandemic" spreading across the globe, Pfizer is taking the fight against antimicrobial resistance (AMR) Down Under. | Pfizer announced Tuesday that it has invested 150 million Australian dollars (about $98 million) to build a new manufacturing facility at its Australian site in Melbourne, where the company will help produce new antimicrobial treatments aimed at addressing the rising tide of antimicrobial resistance.

132

132

Pharmacy Times

AUGUST 6, 2024

Acalabrutinib plus venetoclax, with or without obinutuzumab, demonstrated significant improvements in progression-free survival.

132

132

pharmaphorum

AUGUST 6, 2024

Discover how the innovative geko device is driving clinical change in UK stroke care. Learn how this technology is revolutionising the treatment and management of stroke patients.

131

131

Pharmacy Times

AUGUST 6, 2024

Two different brands of intravenous immunoglobulin have been investigated, finding Brand P led to significantly longer durations of fever and hospitalization when compared to brand T.

Hospitals 132

Hospitals 132

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Pharma

AUGUST 6, 2024

Servier has expanded its IDH drug armamentarium with the FDA approval for an IDH1/2 dual inhibitor. | Servier's Voranigo, or vorasidenib, is now the first systemic therapy for low-grade IDH-mutant brain cancer.

FDA 126

FDA 126

Pharmacy Times

AUGUST 6, 2024

Improvements were observed in both the intervention and control group, with those who had self-reported learning difficulties showing the least improvement.

131

131

STAT

AUGUST 6, 2024

Retirements from the Food and Drug Administration are hardly shocking, especially in the wake of pandemic burnout. But when longtime medical device director Jeff Shuren announced his departure in July, the device world was stunned. Industry leaders, patient advocates, and FDA colleagues alike had grown accustomed to the ambitious, politically-savvy regulator.

FDA 126

FDA 126

Pharmacy Times

AUGUST 6, 2024

An overview of acid reflux and gastroesophageal reflux disease, over-the-counter options, long-term effects of proton pump inhibitors, lifestyle recommendations, and when to refer patients.

123

123

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

AUGUST 6, 2024

Alcohol policy researchers are fuming over a letter sent by members of Congress last month, which criticizes a panel of experts charged with assessing the health risks of drinking alcohol. The letter reflects some of the tensions arising as federal health officials revise dietary guidelines for Americans based on a review of research, including mounting evidence of alcohol-related harms.

124

124

Fierce Healthcare

AUGUST 6, 2024

UnitedHealthcare will launch a national program Oct. 1 for physicians to override traditional prior authorization requirements. | Physician practices in good standing will be able to skip prior authorization for some services, the insurer recently announced.

Insurance 122

Insurance 122

Fierce Pharma

AUGUST 6, 2024

Bayer’s transformation under CEO Bill Anderson has picked up momentum. In reporting second-quarter earnings on Tuesday, the company revealed it has cut 3,200 jobs since the start of this year. | Bayer’s transformation under CEO Bill Anderson has picked up momentum. In reporting second-quarter earnings on Tuesday, the company revealed it has cut 3,200 jobs since the start of this year.

121

121

Pharmacy Times

AUGUST 6, 2024

Sunobinop binds to and activate nociception/orphanin-FQ peptide receptor, which is a known therapeutic target for substance use disorder.

119

119

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

AUGUST 6, 2024

Discover how Step Pharma is harnessing genetics and developing therapeutics targeting CTPS1 to advance cancer research and enhance clinical success. Learn more about their innovative approach.

119

119

Fierce Pharma

AUGUST 6, 2024

As sales from COVID-19 vaccines continue to flounder, lawsuits associated with the products keep on piling up. | The university accused Pfizer's Comirnaty partner of failing to pay the full total of royalties owed on worldwide product sales through a sublicense agreement to Penn's mRNA patents.

Vaccines 119

Vaccines 119

STAT

AUGUST 6, 2024

Life science venture capital firms are pacing for another record-low year of fundraising, potentially hindering the amount of money that startups can draw from over the next several years. In the first half of the year, the industry’s VC firms have raised just 15 pools of capital from wealthy individuals, sovereign wealth funds, pension funds, or university endowments.

118

118

Drug Topics

AUGUST 6, 2024

See what’s trending in pharmacy with a preview of the Total Pharmacy August issue.

112

112

STAT

AUGUST 6, 2024

The U.S. Congress needs help. It lacks the expertise to do its job in the post-Chevron world. At the end of its most recent term, the Supreme Court cast aside in a 6-3 decision the Chevron deference , which for 40 years required judges to defer to reasonable interpretations by federal agencies of the laws they are charged with administering. To legislate effectively without the Chevron deference, Congress will have to enact laws that leave far less room for interpretation.

116

116

Fierce Healthcare

AUGUST 6, 2024

This week on “Podnosis” we're discussing a new payment model that could affect thousands o | This week on “Podnosis” we're discussing a new payment model that could affect thousands of hospitals across the country. It's called TEAM, and it stands for Transforming Episode Accountability Model. It's a mandatory bundled payment program that covers five common procedures.

Hospitals 111

Hospitals 111

STAT

AUGUST 6, 2024

Arie Belldegrun has yet another job: He wants to be your lender. On Tuesday, Belledegrun and his team announced they have raised more than $600 million for a new life science credit firm called Symbiotic Capital. Symbiotic said it will provide loans to biotechs, companies manufacturing medical devices and health care tools, sequencing firms, and synthetic biology companies, and more.

112

112

pharmaphorum

AUGUST 6, 2024

There's a new source of funding for life science companies, Symbiotic Capital, which is providing credit as an alternative to other financing routes

111

111

PioneerRx

AUGUST 6, 2024

Vacations are coming to an end, the temperature is starting to cool down (depending where you are), and your pharmacy’s workflow might.

111

111

Fierce Pharma

AUGUST 6, 2024

Amid Bayer's massive reorganization, the company's pharma group is moving | The company plans to keep building out blockbuster hopeful Nubeqa, popular eye drug Eylea and newer Kerendia as its top-selling Xarelto succumbs to generic competition.

111

111

pharmaphorum

AUGUST 6, 2024

Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech.Agenus revealed BMS' decision in a Securities & Exchange Commission (SEC) filing (PDF), saying it was a result of a "broader strategic realignment of their development pipeline which involves other licensed products.

111

111

Pharmacy Times

AUGUST 6, 2024

A report from SkyQuest Technology highlights the growth in the oncology and insulin spaces, indicating they will contribute to the most growth.

107

107

pharmaphorum

AUGUST 6, 2024

Explore the latest updates and collaborations between the Gates Foundation, UCL, DSRU and more in the May-June 2024 issue of Changing Faces. Learn about their impactful work in government, non-profit, and professional organisation sectors.

110

110

Fierce Healthcare

AUGUST 6, 2024

The country’s four historically Black medical schools have received a total of $600 million in an investment by Bloomberg Philanthropies. | The funding will go to Meharry Medical College, Charles R. Drew University of Medicine and Science, Howard University College of Medicine and Morehouse School of Medicine. The foundation also gave seed funding to help start a new medical school at Xavier University of Louisiana in New Orleans -- a collaboration between Xavier and Ochsner Health.

Medical Schools 106

Medical Schools 106

Fierce Pharma

AUGUST 6, 2024

After previously floating the possibility of div | After previously floating the possibility of divesting Roctavian, BioMarin has decided to keep the hemophilia A gene therapy—but with a narrowed focus. The reorg comes with cost cuts across the medicine's R&D, manufacturing and commercialization support functions.

105

105